Fig. 2: Evolution of clonal hematopoiesis (CH) with and without lenalidomide maintenance.
From: Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma
A Plots demonstrating expansion, reduction or stability of TP53-mutant CH in three groups, measured by differences in variant allelic frequency (VAF) compared to baseline sample. B Box plots comparing VAF for TP53 mutation at three different time points for three groups. C Fishplot showing progression of TP53-mutant CH (E271*) into therapy-related myelodysplastic syndrome.
